Clinical trial
Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat…
NCT00163150 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00163150 |
|---|---|
| Title | Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke |
| Official title | Lacunar-Brain Infarction Cerebral Hyperactivity And Atorvastatin Trial. A Placebo-Controlled Trial Of High-Dose Atorvastatin In Patients With Cerebral Small Vessel Disease. |
| Acronym | LA BICHAT |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Cerebrovascular Accident, Hypercholesterolemia |
| Intervention type | Drug |
| Interventions | Atorvastatin |
| Enrollment | 128 |
| Start date | Jun 1, 2003 |
| Completion | Feb 1, 2006 |
| First posted | Sep 13, 2005 |
| Last update posted | Feb 18, 2021 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: